|271.21||+0.7700||+0.28%||Vol 242.59K||1Y Perf -19.31%|
|Apr 16th, 2021 10:38 DELAYED|
|0.48 0.18%||- -|
|Target Price||294.41||Analyst Rating||Hold 2.68|
|Potential %||8.41||Finscreener Ranking||★★★+ 51.44|
|Insiders Trans % 3/6/12 mo.||100/-/-||Value Ranking||★★★★ 57.13|
|Insiders Value % 3/6/12 mo.||100/-3/-3||Growth Ranking||★★★★+ 65.16|
|Insiders Shares Cnt. % 3/6/12 mo.||100/14/14||Income Ranking||— -|
|Market Cap||41.32B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||34.09||Earnings Date||22nd Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||22nd Apr 2021|
|Estimated EPS Next Report||5.07|
|EPS Growth Next 5 Years %||10.50|
|Avg. Weekly Volume||675.89K|
|Avg. Monthly Volume||947.17K|
|Avg. Quarterly Volume||1.20M|
Biogen Inc. (NASDAQ: BIIB) stock closed at 270.44 per share at the end of the most recent trading day (a 1.75% change compared to the prior day closing price) with a volume of 986.47K shares and market capitalization of 41.32B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.
The one-year performance of Biogen Inc. stock is -19.31%, while year-to-date (YTD) performance is 10.45%. BIIB stock has a five-year performance of 0.72%. Its 52-week range is between 223.25 and 363.92, which gives BIIB stock a 52-week price range ratio of 34.09%
Biogen Inc. currently has a PE ratio of 10.80, a price-to-book (PB) ratio of 3.78, a price-to-sale (PS) ratio of 4.04, a price to cashflow ratio of 10.10, a PEG ratio of 2.32, a ROA of 14.74%, a ROC of 27.76% and a ROE of 31.72%. The company’s profit margin is 26.42%, its EBITDA margin is 42.70%, and its revenue ttm is $9.91 Billion , which makes it $65.06 revenue per share.
Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $5.07 for the next earnings report. Biogen Inc.’s next earnings report date is 22nd Apr 2021.
The consensus rating of Wall Street analysts for Biogen Inc. is Hold (2.68), with a target price of $294.41, which is +8.41% compared to the current price. The earnings rating for Biogen Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biogen Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.31, ATR14 : 8.65, CCI20 : -21.14, Chaikin Money Flow : -0.05, MACD : -1.14, Money Flow Index : 58.45, ROC : -2.04, RSI : 49.05, STOCH (14,3) : 41.21, STOCH RSI : 1.00, UO : 42.32, Williams %R : -58.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Alfred W. Sandrock (Option Excercise at a value of $0), Alfred W. Sandrock (Sold 3 000 shares of value $1 050 000 ), Alphonse Galdes (Option Excercise at a value of $0), Chirfi Guindo (Option Excercise at a value of $0), Ginger Gregory (Option Excercise at a value of $0), Jesus B. Mantas (Buy at a value of $239 766), Michel Vounatsos (Buy at a value of $748 047), Michel Vounatsos (Option Excercise at a value of $0), Robin C. Kramer (Option Excercise at a value of $0), Susan H. Alexander (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.